Zimmer Biomet Holdings Inc (NYSE:ZBH) Shares Sold by Kirr Marbach & Co. LLC IN

Kirr Marbach & Co. LLC IN trimmed its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 1.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,290 shares of the medical equipment provider’s stock after selling 976 shares during the period. Zimmer Biomet makes up approximately 2.4% of Kirr Marbach & Co. LLC IN’s holdings, making the stock its 16th biggest holding. Kirr Marbach & Co. LLC IN’s holdings in Zimmer Biomet were worth $9,870,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisory Services Network LLC grew its position in shares of Zimmer Biomet by 2.7% during the 4th quarter. Advisory Services Network LLC now owns 3,552 shares of the medical equipment provider’s stock worth $369,000 after buying an additional 94 shares in the last quarter. MML Investors Services LLC grew its position in shares of Zimmer Biomet by 3.4% during the 4th quarter. MML Investors Services LLC now owns 2,912 shares of the medical equipment provider’s stock worth $302,000 after buying an additional 96 shares in the last quarter. Utah Retirement Systems grew its position in shares of Zimmer Biomet by 0.3% during the 4th quarter. Utah Retirement Systems now owns 37,952 shares of the medical equipment provider’s stock worth $3,936,000 after buying an additional 100 shares in the last quarter. Louisiana State Employees Retirement System grew its position in shares of Zimmer Biomet by 0.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 10,800 shares of the medical equipment provider’s stock worth $1,379,000 after buying an additional 100 shares in the last quarter. Finally, Belpointe Asset Management LLC grew its position in shares of Zimmer Biomet by 0.8% during the 4th quarter. Belpointe Asset Management LLC now owns 13,808 shares of the medical equipment provider’s stock worth $1,432,000 after buying an additional 106 shares in the last quarter. 89.64% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE ZBH opened at $121.91 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 0.97. The stock has a market capitalization of $25.07 billion, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 2.29 and a beta of 1.19. Zimmer Biomet Holdings Inc has a fifty-two week low of $96.99 and a fifty-two week high of $134.55.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.01. Zimmer Biomet had a positive return on equity of 13.24% and a negative net margin of 3.90%. The business had revenue of $1.98 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the company earned $1.91 earnings per share. The company’s quarterly revenue was down 2.1% on a year-over-year basis. On average, equities analysts anticipate that Zimmer Biomet Holdings Inc will post 7.81 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date was Thursday, March 28th. Zimmer Biomet’s payout ratio is 12.57%.

ZBH has been the topic of a number of recent research reports. Zacks Investment Research downgraded Zimmer Biomet from a “hold” rating to a “sell” rating in a research report on Saturday, April 13th. SunTrust Banks increased their price target on Zimmer Biomet to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, February 5th. Cantor Fitzgerald set a $135.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a research report on Friday, January 25th. Barclays increased their price target on Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a research report on Monday, April 15th. Finally, Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price objective on the stock in a research report on Monday, April 8th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $130.19.

In other news, Director Arthur J. Higgins acquired 500 shares of Zimmer Biomet stock in a transaction dated Friday, February 15th. The stock was purchased at an average cost of $123.28 per share, for a total transaction of $61,640.00. Following the completion of the purchase, the director now directly owns 2,400 shares in the company, valued at approximately $295,872. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Farrell acquired 2,000 shares of Zimmer Biomet stock in a transaction dated Wednesday, February 13th. The stock was purchased at an average price of $123.62 per share, with a total value of $247,240.00. Following the completion of the purchase, the director now owns 2,000 shares of the company’s stock, valued at $247,240. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 4,425 shares of company stock valued at $550,506. Company insiders own 0.72% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zimmer Biomet Holdings Inc (NYSE:ZBH) Shares Sold by Kirr Marbach & Co. LLC IN” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/kirr-marbach-co-llc-in-sells-976-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: Growth and Income Funds

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.